The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic

Citations Over TimeTop 1% of 2009 papers

Abstract

Experimental therapeutics developed to exploit RNA interference (RNAi) are now in clinical studies. Here, the translation from concept to clinic for the first experimental therapeutic to provide targeted delivery of synthetic, small interfering RNA (siRNA) in humans is described. This targeted, nanoparticle formulation of siRNA, denoted as CALAA-01, consists of a cyclodextrin-containing polymer (CDP), a polythethylene glycol (PEG) steric stabilization agent, and human transferrin (Tf) as a targeting ligand for binding to transferrin receptors (TfR) that are typically upregulated on cancer cells. The four component formulation is self-assembled into nanoparticles in the pharmacy and administered intravenously (iv) to patients. The designed features of this experimental therapeutic are described, and their functions illustrated.

Related Papers

• → Transferrin receptor 2: a new molecule in iron metabolism(2003)93 cited
• → Lymphocyte Proliferation Is Controlled by both Iron Availability and Regulation of Iron Uptake Pathways(1992)68 cited
• → Effect of aluminium on iron uptake and transferrin-receptor expression by human erythroleukaemia K562 cells(1990)52 cited
• → Species specificity of iron delivery in hybridomas(1988)11 cited
• → Commentary: Mutations of Transferrin Receptor 2 (Trf-2) and Iron Storage Disease(2001)2 cited